Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Human Peripheral Blood-Derived Endothelial Colony-Forming Cells Are Highly Similar to Mature Vascular Endothelial Cells yet Demonstrate a Transitional Transcriptomic Signature.

Kutikhin AG., Tupikin AE., Matveeva VG., Shishkova DK., Antonova LV., Kabilov MR.

Laboratory Study, published in Cells (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cells (2020)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
32260159
PMCID
PMC7226818
DOI
10.3390/cells9040876
Citations
41

Abstract (original English)

Endothelial colony-forming cells (ECFC) are currently considered as a promising cell population for the pre-endothelialization or pre-vascularization of tissue-engineered constructs, including small-diameter biodegradable vascular grafts. However, the extent of heterogeneity between ECFC and mature vascular endothelial cells (EC) is unclear. Here, we performed a transcriptome-wide study to compare gene expression profiles of ECFC, human coronary artery endothelial cells (HCAEC), and human umbilical vein endothelial cells (HUVEC). Characterization of the abovementioned cell populations was carried out by immunophenotyping, tube formation assay, and evaluation of proliferation capability while global gene expression profiling was conducted by means of RNA-seq. ECFC were similar to HUVEC in terms of immunophenotype (CD31 + vWF + KDR + CD146 + CD34 - CD133 - CD45 - CD90 - ) and tube formation activity yet had expectedly higher proliferative potential. HCAEC and HUVEC were generally similar to ECFC with regards to their global gene expression profile; nevertheless, ECFC overexpressed specific markers of all endothelial lineages ( NRP2 , NOTCH4 , LYVE1 ), in particular lymphatic EC ( LYVE1 ), and had upregulated extracellular matrix and basement membrane genes ( COL1A1 , COL1A2 , COL4A1 , COL4A2 ). Proteomic profiling for endothelial lineage markers and angiogenic molecules generally

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AcetylationCell DifferentiationCell LineCoronary VesselsEndothelial CellsFluorescenceGene Expression ProfilingGene Expression RegulationHuman Umbilical Vein Endothelial CellsHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.